Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT06014762 · ClinicalTrials.gov registry record · Phase 1

P-CD19CD20-ALLO1 Allogeneic CAR-T Cells in the Treatment of Subjects With B Cell Malignancies

A Phase 1 study of High Grade B-Cell Lymphoma and DLBCL, sponsored by Poseida Therapeutics.

Recruiting
Registry status
Phase 1
Development phase
120
Enrollment target
17
Study locations

NCT06014762 is a Phase 1 study of High Grade B-Cell Lymphoma and DLBCL that is actively recruiting participants, run by Poseida Therapeutics. The registered enrollment target is 120 participants, above the 58-participant average among 25 other High Grade B-Cell Lymphoma trials with a reported enrollment target (107% higher). The trial reports 17 study locations across 14 states.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT06014762, a Phase 1 study of High Grade B-Cell Lymphoma and DLBCL, is actively recruiting participants, sponsored by Poseida Therapeutics.

RECRUITING
Registry status
Phase 1
Development phase
120 participants
Enrollment target
17
Study locations

Study Summary

Phase 1 study comprised of open-label, dose escalation and expansion cohort study of P-CD19CD20-ALLO1 allogeneic T stem cell memory (Tscm) CAR-T cells in subjects with relapsed/refractory B cell malignancies

Conditions Studied

High Grade B-Cell Lymphoma DLBCL Diffuse Large B-Cell Lymphoma, Not Otherwise Specified DLBCL - Diffuse Large B Cell Lymphoma Primary Mediastinal Large B-cell Lymphoma (PMBCL) Transformed Follicular Lymphoma (tFL) Follicular Lymphoma Grade 3B Dlbcl NOS DLBCL Arising From Follicular Lymphoma DLBCL, Diffused Large B Cell Lymphoma

Interventions

  • DRUG Rimiducid
  • BIOLOGICAL P-CD19CD20-ALLO1

Study Locations (17)

California

  • University of California San Diego - La Jolla
  • Loma Linda University Cancer Center - Loma Linda
  • Cedars-Sinai Medical Center - Los Angeles

Louisiana

  • Our Lady of the Lake Hospital - Baton Rouge
  • Ochsner Clinic Foundation - New Orleans

Florida

  • Advent Health Orlando - Orlando

Indiana

  • Indiana University - Indianapolis

Michigan

  • Wayne State - Karmanos Cancer Institute - Detroit

New York

  • NYU Grossman School of Medicine - New York

North Carolina

  • UNC Lineberger Comprehensive Cancer Center - Chapel Hill

Ohio

  • University of Cincinnati - Cincinnati

Trial Details

FieldValue
Enrollment Target 120 participants
Start Date 2024-04-16
Est. Completion 2041-03
Phase Phase 1

Sponsor

Poseida Therapeutics

6 total trials

Interested in This Trial?

Full Details on ClinicalTrials.gov ↗

What the Registry Record Tells You About NCT06014762

The ClinicalTrials.gov registry entry for NCT06014762 describes a study currently listed as recruiting, categorized as Phase 1. The registered enrollment target is 120 participants, a figure that helps gauge the scale of data the investigators plan to collect, above the 58-participant average among 25 other High Grade B-Cell Lymphoma trials with a reported enrollment target (107% higher). The listed sponsor is Poseida Therapeutics, which has 6 total studies on file at ClinicalTrials.gov.

The record links to 10 conditions, with High Grade B-Cell Lymphoma appearing as the primary indexed condition, and to 2 interventions - of which Rimiducid is the first listed.

NCT06014762 reports 17 study locations spanning 14 distinct geographic areas - top geographies include California, Louisiana, Florida.

Frequently Asked Questions

What is clinical trial NCT06014762 about?

NCT06014762 is a clinical study titled "P-CD19CD20-ALLO1 Allogeneic CAR-T Cells in the Treatment of Subjects With B Cell Malignancies". Phase 1 study comprised of open-label, dose escalation and expansion cohort study of P-CD19CD20-ALLO1 allogeneic T stem cell memory (Tscm) CAR-T cells in subjects with relapsed/refractory B cell malignancies

What is the current status of trial NCT06014762?

This trial is currently recruiting. It is a Phase 1 study. The enrollment target is 120 participants. The study started on 2024-04-16. Estimated completion is 2041-03.

What conditions does trial NCT06014762 study?

This clinical trial studies the following conditions: High Grade B-Cell Lymphoma, DLBCL, Diffuse Large B-Cell Lymphoma, Not Otherwise Specified, DLBCL - Diffuse Large B Cell Lymphoma, Primary Mediastinal Large B-cell Lymphoma (PMBCL).

What interventions are being tested in trial NCT06014762?

The interventions under investigation include: Rimiducid (DRUG), P-CD19CD20-ALLO1 (BIOLOGICAL).

Who is sponsoring clinical trial NCT06014762?

This trial is sponsored by Poseida Therapeutics, which has 6 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT06014762 being conducted?

This trial has 17 study locations across California, Florida, Indiana, Louisiana, Michigan. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Learn More About Clinical Trials

Similar trials for High Grade B-Cell Lymphoma

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Explore more on PlainTrial

High Grade B-Cell Lymphoma

All registered trials for this condition

DLBCL

All registered trials for this condition

California

All trials with a study site in California

Recruiting now

Find trials open to new participants near you

Rankings

Top sponsors, conditions, and phases

Read our methodology - how this data is sourced, computed, and verified.

Related

Browse all → | Rankings →
Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.